Monash antibodies, Adelaide protein gels
Thursday, 22 January, 2009
Monash University has signed a deal with Danish pathology and cancer diagnostics specialist Dako to develop monoclonal antibodies for cancer research and treatment.
The Monash Antibody Technologies Facility (MATF), opened in September last year, will develop high-affinity antibodies for what it called “global commercialisation opportunities”.
MATF director Alan Sawyer said in a statement that the collaboration was part of the facility’s vision to provide the international research and diagnostics community with the best reagents possible.
Meanwhile, the Adelaide Proteomics Centre has decided to adopt publicly listed Fluorotechnics’ range of 2D gels and dyes for protein detection.
The centre has also agreed to become Fluorotechnics’ Australian reference customer and promote the company’s gels in Australia and internationally.
A neuroscientist and biochemist's antiviral lightbulb moment
While studying how certain processes work inside the human brain, an Australian scientist...
Antimicrobial resistance in children rises globally — 100K+ samples reveal
Spanning 82 countries, there was an increase in every region between 2004 and 2022, with the...
Robotic laboratory to fast-track drug invention, trials and commercialisation
The lab will house an automated system for high-throughput X-ray crystallography, often referred...
